Lay Summaries and Lay Summary Videos

• PRADAXA ® - Atrial Fibrillation

  Clinical Study Number	1160.204
  Study Indication	Atrial Fibrillation
  Product	PRADAXA ®
  Generic Name	Dabigatran
  Lab Code
  Clinical Phase	IV
  Study Title	Randomised Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral antIcoagulation sTrategy (The RE-CIRCUIT Trial)
  Study Document	Lay summary 1160.204 english

• PRADAXA ® - Atrial Fibrillation

  Clinical Study Number	1160.186
  Study Indication	Atrial Fibrillation
  Product	PRADAXA ®
  Generic Name	Dabigatran
  Lab Code
  Clinical Phase	IIIb
  Study Title	A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110 mg and 150 mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting (RE-DUAL PCI)
  Study Document	Lay summary 1160.186 english

• PRADAXA ® - Venous Thromboembolism

  Clinical Study Number	1160.248
  Study Indication	Venous Thromboembolism
  Product	PRADAXA ®
  Generic Name	Dabigatran
  Lab Code
  Clinical Phase	III
  Study Title	RE-SPECT CVT: a randomised, open-label, exploratory trial with blinded endpoint adjudication (PROBE), comparing efficacy and safety of oral dabigatran etexilate versus oral warfarin in patients with cerebral venous and dural sinus thrombosis over a 24-week period
  Study Document	Lay summary 1160.248 english